title: PD-L1(CD274) promoter methylation predicts survival in colorectal cancer patients.
abstract: This study evaluates promoter methylation of the programmed cell death ligand 1 (PD-L1) as a biomarker in a cohort of 383 colorectal cancer patients.PD-L1methylation (mPD-L1) was inversely correlated with PD-L1 mRNA expression (p= 0.001) and was associated with significantly shorter overall survival (OS,p= 0.003) and recurrence-free survival (RFS,p< 0.001). In age-stratified multivariate Cox proportional hazards analyses including sex, tumor, nodal, distant metastasis categories, microsatellite instability (MSI)-status, and PD-L1 mRNA, mPD-L1is classified as an independent prognostic factor (OS:p= 0.030; RFS:p< 0.001). Further studies are needed to evaluatePD-L1methylation as a biomarker for response prediction of immunotherapies targeting the PD-1/PD-L1 axis.
authors.affiliation: Institute of Pathology, University Hospital Bonn , Bonn, Germany.
authors.forename: Diane
authors.initials: D
authors.lastname: Goltz
authors.affiliation: Institute of Pathology, University Hospital Bonn , Bonn, Germany.
authors.forename: Heidrun
authors.initials: H
authors.lastname: Gevensleben
authors.affiliation: Department of Otolaryngology, Head and Neck Surgery, University Hospital Bonn , Bonn, Germany.
authors.forename: Jörn
authors.initials: J
authors.lastname: Dietrich
authors.affiliation: Institute of Pathology, University Hospital Bonn, Bonn, Germany; Department of Otolaryngology, Head and Neck Surgery, University Hospital Bonn, Bonn, Germany.
authors.forename: Dimo
authors.initials: D
authors.lastname: Dietrich
keywords: CD274; DNA methylation; PD-L1; colorectal cancer; immunotherapeutic; immunotherapies; immunotherapy; microsatellite instability; prognostic biomarker